Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

121. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke) Full Text available with Trip Pro

Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke) The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone reduced the risk for a composite outcome of stroke or myocardial infarction among nondiabetic patients with insulin resistance and a recent stroke or transient ischemic attack. The current planned secondary (...) strokes (HR, 0.72; 95% CI, 0.57-0.91; P=0.005) but had no effect on risk for hemorrhagic events (HR, 1.00; 95% CI, 0.50-2.00; P=1.00).Pioglitazone was effective for secondary prevention of ischemic stroke in nondiabetic patients with insulin resistance.URL: https://www.clinicaltrials.gov. Unique identifier: NCT00091949.© 2017 American Heart Association, Inc.

2018 EvidenceUpdates

122. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? | CADTH.ca CADTH Document Viewer Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Table of Contents Search this document Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? January 2018 Summary There are two major (...) categories of diabetes. Type 1 diabetes (T1D) is characterized by severe impairment or an absolute deficiency of insulin due to autoimmune destruction of pancreatic cells. Type 2 diabetes (T2D) is characterized by a combination of insulin resistance and decreased insulin secretion. Insulin is the mainstay of treatment for T1D. However, it may be difficult for some patients to reach target glycated hemoglobin (A1C) levels on insulin monotherapy. In some cases, hypoglycemia, excessive glucose fluctuations

2018 CADTH - Issues in Emerging Health Technologies

123. GLP-1 and Insulin Recruit Muscle Microvasculature and Dilate Conduit Artery Individually But Not Additively in Healthy Humans Full Text available with Trip Pro

GLP-1 and Insulin Recruit Muscle Microvasculature and Dilate Conduit Artery Individually But Not Additively in Healthy Humans Glucagon-like peptide-1 (GLP-1) and insulin increase muscle microvascular perfusion, thereby increasing tissue endothelial surface area and nutrient delivery.To examine whether GLP-1 and insulin act additively on skeletal and cardiac microvasculature and conduit artery.Healthy adults underwent three study protocols in random order.Clinical Research Unit at the University (...) of Virginia.Overnight-fasted participants received an intravenous infusion of GLP-1 (1.2 pmol/kg/min) or normal saline for 150 minutes with or without a 2-hour euglycemic insulin clamp (1 mU/kg/min) superimposed from 30 minutes onward. Skeletal and cardiac muscle microvascular blood volume (MBV), flow velocity, and flow; brachial artery diameter, flow velocity, and blood flow; and pulse wave velocity (PWV) were measured.GLP-1 significantly increased skeletal and cardiac muscle MBV and microvascular blood flow (MBF

2018 Journal of the Endocrine Society

124. A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1 Full Text available with Trip Pro

A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1 29404506 2019 01 18 2471-254X 2 1 2018 01 Hepatology communications Hepatol Commun A new mechanism of action of glucagon-like peptide-1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen-related cell adhesion molecule 1. 9-12

2018 Hepatology communications

125. Insulin Pumps for the Management of Type 2 Diabetes: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Insulin Pumps for the Management of Type 2 Diabetes: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Insulin Pumps for the Management of Type 2 Diabetes: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Insulin Pumps for the Management of Type 2 Diabetes: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Insulin Pumps for the Management of Type 2 Diabetes: A Review of Clinical Effectiveness (...) , Cost-Effectiveness and Guidelines Last updated: October 26, 2018 Project Number: RC1033-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of insulin pumps for the treatment of type 2 diabetes in children, adolescents, or adults? What is the cost-effectiveness of insulin pumps for the treatment of type 2 diabetes in children, adolescents, or adults? What are the evidence-based guidelines for the use

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

126. Insulin Pumps for Patients with Any Diabetes Type: Clinical Effectiveness and Guidelines

Insulin Pumps for Patients with Any Diabetes Type: Clinical Effectiveness and Guidelines Insulin Pumps for Patients with Any Diabetes Type: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Insulin Pumps for Patients with Any Diabetes Type: Clinical Effectiveness and Guidelines Insulin Pumps for Patients with Any Diabetes Type: Clinical Effectiveness and Guidelines Last updated: December 13, 2018 Project Number: RB1288-000 Product Line: Research Type: Devices (...) and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of insulin pumps for patients with any type of diabetes? What are the evidence-based guidelines associated with use of insulin pumps for patients with any type of diabetes? Key Message Six systematic reviews with meta-analyses, eight randomized controlled trials, and one evidence-based guideline were identified regarding the clinical effectiveness and safety of insulin pumps for pediatric

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

127. Soliqua - lixisenatide + insulin glargine - Diabetes mellitus, Type 2

Soliqua - lixisenatide + insulin glargine - Diabetes mellitus, Type 2 lixisenatide + insulin glargine | CADTH.ca Find the information you need lixisenatide + insulin glargine lixisenatide + insulin glargine Last Updated: January 3, 2019 Result type: Reports Project Number: SR0564-000 Product Line: Generic Name: lixisenatide + insulin glargine Brand Name: Soliqua Manufacturer: sanofi-aventis Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria 1 (...) : Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when oral glucose-lowering medicinal products combined with basal insulin, or basal insulin alone do not provide adequate glycaemic control. Submission Type: New Combination Project Status: Complete Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: December 24, 2018 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee Schedule: Schedule

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

128. Effect of Bolus Insulin Administration Followed by a Continuous Insulin Infusion on Diabetic Ketoacidosis Management. Full Text available with Trip Pro

Effect of Bolus Insulin Administration Followed by a Continuous Insulin Infusion on Diabetic Ketoacidosis Management. Despite the high incidence of diabetic ketoacidosis (DKA) there is no consensus on the most appropriate way to manage insulin therapy. This study was conducted to evaluate the effect of an insulin bolus on the resolution of DKA. A retrospective chart review of patients admitted between 1 September 2014 and 30 June 2016 with a diagnosis of DKA was conducted. Patients were (...) assigned to the bolus or no bolus group based on provider preference. All patients were initiated on a 0.1 unit/kilogram (kg)/hour (h) intravenous (IV) regular insulin infusion, and patients in the bolus group were treated with a 0.1 unit/kg IV regular insulin bolus. Of the 145 admissions evaluated, 58 received a bolus and 87 did not. There was no difference in baseline demographics, except baseline blood glucose was higher in the bolus group (653 vs. 591 milligrams (mg)/deciliter (dL), p = 0.04

2018 Pharmacy (Basel, Switzerland) Controlled trial quality: uncertain

129. Effects of Local Use of Insulin on Wound Healing in Non-diabetic Patients. Full Text available with Trip Pro

Effects of Local Use of Insulin on Wound Healing in Non-diabetic Patients. Clinical trials have shown the positive effects of local insulin therapy in the formation of new vessels and fibrosis in acute and chronic diabetic wounds without major adverse effects.The aim of this study was to investigate the effects of local insulin use on wound healing in non-diabetic patients.A randomized, split-plot, double-blind, placebo-controlled trial was conducted. Ten non-diabetic patients with full (...) -thickness acute wounds were recruited (5 due to trauma, 3 to burns, and 2 to pressure). All wounds received standard bedside treatment. Each wound was divided into 2 zones. One side received a standard care plus insulin, while the other received standard care plus injection of saline solution. A biopsy specimen was taken from both sites on days 0 and 14. The amount of blood vessel growth and the percentage of fibrosis were evaluated.A significant difference in the number of new vessels was observed

2018 Plastic surgery (Oakville, Ont.) Controlled trial quality: uncertain

130. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. (Abstract)

Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. 29610904 2018 04 03 1539-3704 168 7 2018 Apr 03 Annals of internal medicine Ann. Intern. Med. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. 525-526 10.7326/L17-0705 Haak Thomas T Diabetes Center Mergentheim, Bad Mergentheim, Germany (T.H.). eng Journal Article United States Ann Intern Med

2018 Annals of Internal Medicine Controlled trial quality: uncertain

131. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. (Abstract)

Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. 29610905 2018 04 03 1539-3704 168 7 2018 Apr 03 Annals of internal medicine Ann. Intern. Med. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. 526-527 10.7326/L17-0706 Beck Roy W RW Jaeb Center for Health Research, Tampa, Florida (R.W.B., T.D.R.). Riddlesworth Tonya D TD Jaeb Center for Health

2018 Annals of Internal Medicine Controlled trial quality: uncertain

132. The Effect of Preoperative Oral Carbohydrate Administration on Insulin Resistance and Comfort Level in Patients Undergoing Surgery. (Abstract)

The Effect of Preoperative Oral Carbohydrate Administration on Insulin Resistance and Comfort Level in Patients Undergoing Surgery. The aim of this study was to evaluate the effect of preoperative oral carbohydrate solution (OCS) administration on postoperative insulin resistance and patient comfort in elective laparoscopic cholecystectomy.Randomized controlled clinical study.The experimental group received OCS. The control group did not eat or drink before surgery. Glucose and insulin level (...) were measured at baseline, 2 hours before surgery, and at the first and third hour after surgery. Insulin resistance was assessed by the homeostasis model assessment of insulin resistance (HOMA-IR). The visual analogue scale (VAS) and general comfort scale (GCS) were used to assess postoperative comfort level.A significant increase in the glucose level was observed in both groups (P < 0.05). A change in glucose level was significantly higher in the control group (P = .014). HOMA-IR values did

2018 Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses Controlled trial quality: uncertain

133. Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial (Abstract)

Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial This prospective, multicentre, phase III study (NCT02104804) evaluated the efficacy and safety of saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin ± metformin. Patients with glycated haemoglobin (HbA1c) 7.5% to 10.5% and fasting (...) plasma glucose (FPG) <15 mmol/L (270 mg/dL) on stable insulin therapy (20-150 U/d) were randomized (1:1) to saxagliptin 5 mg once daily (N = 232) or placebo (N = 230) for 24 weeks, stratified by metformin use. The primary efficacy measure was change in HbA1c. Saxagliptin treatment resulted in a greater adjusted mean change in HbA1c from baseline to week 24 than placebo (-0.58%; P < .001), irrespective of metformin use, and a greater mean change in FPG (0.9 mmol/L [-15.9 mg/dL]; P < .001). More

2018 EvidenceUpdates

134. Insulin glargine 300 IU/mL solution (Toujeo) for diabetes mellitus

Insulin glargine 300 IU/mL solution (Toujeo) for diabetes mellitus Insulin glargine 300 IU/mL solution (Toujeo) for diabetes mellitus - NPS MedicineWise Log In Menu Featured topics Professional development NPS Publications An independent peer-reviewed journal providing critical commentary on drugs and therapeutics. Timely, independent, evidence-based information on new drugs and medical tests, and changes to the PBS and MBS. Featured topics Talk to a professional Information for consumers (...) -based information for Australian health professionals and consumers. Featured resources 2 October 2019 2 October 2019 26 September 2019 Featured topic 20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Partner with us Latest projects Search Search Search Search POPULAR Log in Log in All fields are required Email address* Password* Log in Insulin glargine 300 IU/mL solution (Toujeo) for diabetes mellitus A long-acting insulin for adults

2018 National Prescribing Service Limited (Australia)

135. Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V

Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Insulin glargin/Lixisenatid (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 May 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text (...) is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-16 Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-16 Version 1.0 Insulin glargine/lixisenatide (type 2 diabetes mellitus) 20 May 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin glargine/lixisenatide (type

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

138. Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin

Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.4, 27 July 2018 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment Continuous glucose monitoring (CGM real-time) and flash glucose (...) monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin Project ID: OTJA08 This report is part of the project / joint action ‘724130 / EUnetHTA JA3’ which has received funding from the European Union’s Health Programme (2014-2020) Continuous (real-time) and flash glucose monitoring as personal, standalone systems in patients with DM treated with insulin Version 1.4, 27 July 2018 EUnetHTA Joint Action 3 WP4 2 DOCUMENT HISTORY AND CONTRIBUTORS Version Date

2018 EUnetHTA

139. insulin degludec (Tresiba)

insulin degludec (Tresiba) insulin degludec | CADTH.ca Find the information you need insulin degludec insulin degludec Last Updated: January 19, 2018 Result type: Reports Project Number: SR0521-000 Product Line: Generic Name: insulin degludec Brand Name: Tresiba Manufacturer: Novo Nordisk Canada Inc. Indications: Diabetes mellitus, Type 1 & 2 Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: November 20, 2017 Recommendation Type: Reimburse with clinical (...) report(s) sent to applicant and drug plans October 30, 2017 Embargo 4 period ended and validation of redacted CDR review report(s) received November 13, 2017 CDEC Final Recommendation issued to applicant and drug plans November 20, 2017 CDEC Final Recommendation posted 5 November 22, 2017 Final CDR review report(s) and patient input posted 5 December 15, 2017 Tags diabetes mellitus, diabetes mellitus, type 1, diabetes mellitus, type 2, diabetes, Tresiba; insulin degludec Files Related Content Follow

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

140. Early Intensive Insulin Use May Preserve β-Cell Function in Neonatal Diabetes Due to Mutations in the Proinsulin Gene Full Text available with Trip Pro

Early Intensive Insulin Use May Preserve β-Cell Function in Neonatal Diabetes Due to Mutations in the Proinsulin Gene Although mutations in the proinsulin gene (INS) are the second most common cause of neonatal diabetes mellitus, the natural history of β-cell death and the most appropriate treatments remains unknown. We describe the management and outcome of two sisters with INS-mediated diabetes (S1 and S2) and suggest that more intensive insulin treatment of S2 may have resulted in better (...) clinical outcomes. S1 was diagnosed with diabetes after presenting with serum glucose of 404 mg/dL (22.4 mmol/L) and started multiple daily insulin injections at age 4 months, followed by continuous subcutaneous insulin infusion (CSII) at age 42 months. S1 had positive genetic testing at age 4 months for the GlyB8Ser or Gly32Ser mutation in proinsulin. S2 had positive research-based genetic testing, age 1 month, before she had consistently elevated blood glucose levels. Continuous glucose monitoring

2017 Journal of the Endocrine Society